Saudi medical journal · 2025
Phase IV clinical trials for the treatment of non-small cell lung carcinoma (NSCLC): A systemic review from 2020-2025.
СтатьяСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kariri Yousif A, Alqasmi Mohammed H, Alqahtani Bijad S
Аннотация
OBJECTIVE: To evaluate and provide evidence on drugs investigated in completed phase IV clinical trials for adult non-small cell lung carcinoma (NSCLC) therapy, primarily focusing on treatment objectives and adverse effects.
METHODS: Clinical research studies from January 2020 to January 2025 were systematically reviewed using the "ClinicalTrials.gov" database. The inclusion criteria focused on publicly available, relevant, and completed Phase IV studies limited to "Clinicaltrials.gov", while those not meeting these specifications were excluded. As of 3 January 2025, a total of 7,541 Phase IV clinical trials were available on "ClinicalTrials.gov", of which 121 were related to NSCLC.
RESULTS: Six of these clinical studies met the requirements for inclusion in the current investigation. The pharmacological agents investigated in these Phase IV trials were dacomitinib, lorlatinib, durvalumab, osimertinib, and a combination of rivaroxban and sotorasib. Treatment options for NSCLC remain limited due to its complex nature and frequent co-occurrence with other respiratory infections.
CONCLUSION: The studies reviewed reported high rates of adverse events, alongside reduced subjective outcomes and faster response periods. This warrants for continuous research to develop safer and more efficient therapy methods for NSCLC patients.PROSPERO No.: CRD420251038011.
METHODS: Clinical research studies from January 2020 to January 2025 were systematically reviewed using the "ClinicalTrials.gov" database. The inclusion criteria focused on publicly available, relevant, and completed Phase IV studies limited to "Clinicaltrials.gov", while those not meeting these specifications were excluded. As of 3 January 2025, a total of 7,541 Phase IV clinical trials were available on "ClinicalTrials.gov", of which 121 were related to NSCLC.
RESULTS: Six of these clinical studies met the requirements for inclusion in the current investigation. The pharmacological agents investigated in these Phase IV trials were dacomitinib, lorlatinib, durvalumab, osimertinib, and a combination of rivaroxban and sotorasib. Treatment options for NSCLC remain limited due to its complex nature and frequent co-occurrence with other respiratory infections.
CONCLUSION: The studies reviewed reported high rates of adverse events, alongside reduced subjective outcomes and faster response periods. This warrants for continuous research to develop safer and more efficient therapy methods for NSCLC patients.PROSPERO No.: CRD420251038011.